BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31970440)

  • 1. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.
    Jordaens S; Cooksey L; Freire Boullosa L; Van Tendeloo V; Smits E; Mills KI; Orchard KH; Guinn BA
    Cancer Immunol Immunother; 2020 May; 69(5):867-877. PubMed ID: 31970440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
    Kantarjian H; Jabbour E
    Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    Jordaens S; Cooksey L; Bonney S; Orchard L; Coutinho M; Van Tendeloo V; Mills KI; Orchard K; Guinn BA
    Br J Haematol; 2020 May; 189(3):500-512. PubMed ID: 32064588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
    Beyar-Katz O; Gill S
    Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.
    Castro FV; McGinn OJ; Krishnan S; Marinov G; Li J; Rutkowski AJ; Elkord E; Burt DJ; Holland M; Vaghjiani R; Gallego A; Saha V; Stern PL
    Leukemia; 2012 Jul; 26(7):1487-98. PubMed ID: 22266911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
    Corthals SL; Wynne K; She K; Shimizu H; Curman D; Garbutt K; Reid GS
    Br J Haematol; 2006 Feb; 132(4):452-8. PubMed ID: 16412017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
    Le Jeune C; Thomas X
    Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant.
    Shand JC; Jansson J; Hsu YC; Campbell A; Mullen CA
    Cancer Immunol Immunother; 2010 Nov; 59(11):1633-44. PubMed ID: 20602231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
    Maia S; Haining WN; Ansén S; Xia Z; Armstrong SA; Seth NP; Ghia P; den Boer ML; Pieters R; Sallan SE; Nadler LM; Cardoso AA
    Cancer Res; 2005 Nov; 65(21):10050-8. PubMed ID: 16267031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.